{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:14:08Z","timestamp":1794946448681,"version":"4.9.1"},"reference-count":42,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/na","name":"Medsyn Biopharma","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"University of Michigan Comprehensive Cancer Center Core Grant from the National Cancer Institute, NIH","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>KRAS G12D and G12V mutants account for &amp;gt;50% of human cancers carrying a mutated KRAS protein, and targeting KRAS proteins by induced protein degradation represents an attractive cancer therapeutic strategy. Herein, we present the design, synthesis, and evaluation of PROTAC KRAS degraders using a novel cereblon ligand, which led to the discovery of CW-10201 as a promising KRAS degrader. CW-10201 effectively induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cells and attained IC50 values of 2\u20134 nM in inhibition of cell growth in cancer cell lines carrying KRASG12D or KRASG12V mutation. It demonstrated excellent pharmacokinetic and pharmacodynamic properties in mice. CW-10201 was capable of attaining tumor regression in the SW1990 KRASG12D mutated xenograft tumor model and effectively inhibited tumor growth in the SW620 KRASG12V xenograft tumor model in mice at well-tolerated doses. CW-10201 represents a promising KRASG12D and KRASG12V degrader for extensive evaluation and optimization for the treatment of human cancers.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01153","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:02:04Z","timestamp":1787058124000},"page":"20520-20539","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of\nHighly Efficacious CRBN-Based KRAS Degraders\nTargeting Cancers with KRAS G12D and G12V Mutations"],"prefix":"10.1021","volume":"69","author":[{"given":"Changwei","family":"Wang","sequence":"first","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-8575","authenticated-orcid":true,"given":"Prithwish","family":"Ghosh","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Jin","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longchuan","family":"Bai","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0946-9170","authenticated-orcid":true,"given":"Angelo","family":"Aguilar","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McEachern","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Li","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wen","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]},{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]},{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-6950","authenticated-orcid":true,"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]},{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]},{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]},{"name":"University of Michigan , , , ,","place":["Ann Arbor, Michigan, United States, 48109"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026091009071208300_cit1","volume-title":"Cancer Facts & Figures","author":"American Cancer Society.","year":"2025"},{"issue":"1","key":"2026091009071208300_cit2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape\nof KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"Npj Precis. Oncol."},{"issue":"4","key":"2026091009071208300_cit3","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting\nKRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"issue":"7477","key":"2026091009071208300_cit4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C)\ninhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"7781","key":"2026091009071208300_cit5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C)\ninhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026091009071208300_cit6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C Inhibitor\nMRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant\nCancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer\nDiscovery"},{"issue":"6","key":"2026091009071208300_cit7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00245","article-title":"Landscape\nof KRAS G12C\n, Associated Genomic Alterations, and Interrelation With Immuno-Oncology\nBiomarkers in KRAS -Mutated Cancers","volume":"6","author":"Salem","year":"2022","journal-title":"JCO Precis.\nOncol."},{"issue":"2","key":"2026091009071208300_cit8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/jcm12020709","article-title":"KRAS Mutations in Solid\nTumors: Characteristics, Current Therapeutic Strategy, and Potential\nTreatment Exploration","volume":"12","author":"Yang","year":"2023","journal-title":"J. Clin. Med."},{"issue":"4","key":"2026091009071208300_cit9","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of\nMRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026091009071208300_cit10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor\nefficacy of a potent and\nselective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"2026091009071208300_cit11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-026-00763-7","article-title":"Systematic\nand precise interventions for KRAS-mutant cancers","volume":"15","author":"Liang","year":"2026","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"2026091009071208300_cit12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","article-title":"Emerging landscape\nof KRAS inhibitors in cancer treatment","volume":"44","author":"Riedl","year":"2026","journal-title":"Cancer\nCell"},{"issue":"4_Suppl","key":"2026091009071208300_cit13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety,\nefficacy, and on-treatment circulating\ntumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON)\nmulti-selective, tri-complex inhibitor, in patients with RAS mutant\npancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J.\nClin. Oncol."},{"issue":"3","key":"2026091009071208300_cit14","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"Safety\nand clinical activity of daraxonrasib\n(RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"2026091009071208300_cit15","unstructured":"Revolution Medicines, Inc. (Responsible Party).\n          \n          Phase\n3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated\nMetastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302), 2026. https:\/\/clinicaltrials.gov\/study\/NCT06625320."},{"key":"2026091009071208300_cit16","doi-asserted-by":"publisher","first-page":"B107","DOI":"10.1158\/1535-7163.TARG-25-B107","article-title":"Abstract B107:\nPreclinical activity\nof ARV-806, a PROTAC KRAS G12D degrader","volume":"24","author":"Smith","year":"2025","journal-title":"Mol.\nCancer Ther."},{"issue":"7","key":"2026091009071208300_cit17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164413","article-title":"Kras oncogene ablation\nprevents resistance in advanced lung adenocarcinomas","volume":"133","author":"Salmo\u0301n","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2026091009071208300_cit18","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted\nanti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"2026091009071208300_cit19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader\nASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"2026091009071208300_cit20","doi-asserted-by":"publisher","first-page":"TPS3178","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3178","article-title":"Trial in progress: Phase 1 study of the selective protein\ndegrader ASP4396 in patients with locally advanced or metastatic solid\ntumors with KRAS G12D mutations","volume":"43","author":"Sen","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"S2","key":"2026091009071208300_cit21","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"6080\nPreliminary safety and clinical activity\nof ASP3082, a first-in-class, KRAS G12D selective protein degrader\nin adults with advanced pancreatic (PC), colorectal (CRC), and non-small\ncell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Annals Oncol."},{"key":"2026091009071208300_cit22","unstructured":"PAQ Therapeutics, Inc.\n          \n          A Study\nof PT0253 in Participants\nWith KRAS G12D Mutated Advanced Solid Tumors. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06797336?term=PT0253&rank=1."},{"key":"2026091009071208300_cit23","unstructured":"Arvinas Inc.\n          \n          A Study to Evaluate\nARV-806 in Adults\nWith Advanced Cancer That Has the KRAS G12D Mutation. 2026. https:\/\/www.clinicaltrials.gov\/study\/NCT07023731."},{"key":"2026091009071208300_cit24","unstructured":"PAQ Therapeutics Announces $39 Million Series B\nFinancing And Initiates\nPhase 1 Trial To Advance Novel Approach Addressing KRAS-Driven Cancers\nWith High Unmet Need; PAQ Therapeutics, 2025. https:\/\/www.prnewswire.com\/news-releases\/paq-therapeutics-announces-39-million-series-b-financing-and-initiates-phase-1-trial-to-advance-novel-approach-addressing-kras-driven-cancers-with-high-unmet-need-302447786.html."},{"issue":"19","key":"2026091009071208300_cit25","doi-asserted-by":"publisher","first-page":"20103","DOI":"10.1021\/acs.jmedchem.5c01034","article-title":"ZJK-807: A\nSelective PROTAC Degrader of KRAS(G12D) Overcoming Resistance in Pancreatic\nCancer","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026091009071208300_cit26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1021\/acsmedchemlett.4c00487","article-title":"Advances\nin Cancer Treatment and Monitoring: Insights from KRAS Inhibitors\nand Germline Epitope Burden Monitoring","volume":"15","author":"Kargbo","year":"2024","journal-title":"ACS\nMed. Chem. Lett."},{"issue":"2","key":"2026091009071208300_cit27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design,\nSynthesis, and Biological Evaluation of Potent and Selective PROTAC\nDegraders of Oncogenic KRAS G12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026091009071208300_cit28","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and Characterization\nof\nRP03707: A Highly Potent and Selective KRAS(G12D) PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026091009071208300_cit29","unstructured":"American Cancer Society.\n          \n          Cancer\nFacts and Figures\n2023, 2023. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf."},{"issue":"6715","key":"2026091009071208300_cit30","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with\nsmall-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"7","key":"2026091009071208300_cit31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1021\/acsmedchemlett.4c00263","article-title":"Advancements\nin Protein Degradation for Cancer Therapy","volume":"15","author":"Kargbo","year":"2024","journal-title":"ACS\nMed. Chem. Lett."},{"key":"2026091009071208300_cit32","unstructured":"Luo, R.; Liu, J.; Huang, P.; Su, J.; Feng, Y.; Liu, K.; Fan, J.; He, W.; Qian, Y.\n          Glutarimide-containing\npan-kras-mutant\ndegrader compounds and uses thereof. WO 2,024,118,966 A1. 2024."},{"key":"2026091009071208300_cit33","unstructured":"Astellas Pharma Inc.\n          \n          A Study to Find a Suitable\nDose of ASP5834 in Adults With Solid Tumors. 2026. https:\/\/clinicaltrials.gov\/study\/NCT07094204."},{"key":"2026091009071208300_cit34","volume-title":"A Study\nOf PT0511 In Participants\nWith KRAS Mutated Or Amplified Advanced Solid Tumors, NCT07300150","author":"PAQ Therapeutics, Inc.","year":"2026"},{"key":"2026091009071208300_cit35","unstructured":"Astellas Pharma Inc.\n          \n          A Study to Evaluate the Effectiveness\nand Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX\nChemotherapies, in People With Pancreatic Cancer. 2026. https:\/\/clinicaltrials.gov\/study\/NCT07409272."},{"key":"2026091009071208300_cit36","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a Potent and\nOrally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex\nInhibitor for the Treatment of Patients with Multiple RAS-Addicted\nCancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026091009071208300_cit37","unstructured":"Yoshinari, T.; Watanabe, H.; Ishioka, H.; Kawaminami, E.; Kawaguchi, K.; Takahashi, F.; Kamikubo, T.; Imaizumi, T.; Morikawa, T.; Hamaguchi, H.; et al.; Heterocyclic\ncompound that acts on G12D mutant KRAS protein, EP 4,559,906 A1, 2025."},{"issue":"23","key":"2026091009071208300_cit38","doi-asserted-by":"publisher","first-page":"20933","DOI":"10.1021\/acs.jmedchem.4c01401","article-title":"Discovery\nof ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC\nDegrader of Estrogen Receptor alpha (ERalpha)","volume":"67","author":"Rej","year":"2024","journal-title":"J. Med. Chem."},{"issue":"20","key":"2026091009071208300_cit39","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474\u2500a\nPotent, Selective, and Orally Bioavailable IRAK4 Degrader for the\nTreatment of Autoimmune Diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026091009071208300_cit40","doi-asserted-by":"publisher","first-page":"19010","DOI":"10.1021\/acs.jmedchem.4c01521","article-title":"Discovery of ERD-1233 as a Potent\nand Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment\nof ER+ Human Breast Cancer","volume":"67","author":"Acharyya","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026091009071208300_cit41","doi-asserted-by":"publisher","first-page":"118555","DOI":"10.1016\/j.ejmech.2025.118555","article-title":"An overview\nof KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS\nin targeting KRAS G12D using diverse therapeutic modalities","volume":"305","author":"Kumar","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"2026091009071208300_cit42","doi-asserted-by":"publisher","first-page":"130087","DOI":"10.1016\/j.bmcl.2024.130087","article-title":"Discovery of novel\ntetracyclic quinazolines as multi-KRAS inhibitors for the treatment\nof solid tumors","volume":"118","author":"Hong","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01153","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/17\/20520\/66805073\/acs.jmedchem.6c01153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/17\/20520\/66805073\/acs.jmedchem.6c01153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:12:35Z","timestamp":1789045955000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/17\/20520\/5272369\/Discovery-of-Highly-Efficacious-CRBN-Based-KRAS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01153","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01153.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01153.s002","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}